DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to subsets with effector cell function, and ultimately the retention of antigen-responsive lymphocytes with a memory cell phenotype. The initial increase of responsive lymphocytes is followed by an equally dramatic contraction of the responding population. The characteristic contraction of the number of responding lymphocytes that occurs following the antigen-driven expansion phase is caused, at the molecular level, by a change in the balance of intracellular proteins that are responsible for inhibiting or committing a cell to apoptosis via a programmed cell death pathway. Thus, during the initial antigen-driven expansion phase the level of anti-apoptotic protein(s) is increased and the cell is resistant to programmed cell death. Subsequently the level of these anti-apoptotic proteins declines placing the cell at risk for subsequent events conventionally termed activation-induced cell death.
It is the hypothesis of this study that specific immune responses can be inhibited or destroyed at the clonal response level, by preventing the development of the increased level of anti-apoptotic protein(s) that develop during the initial response at the stage of antigen stimulation. Prevention of the production of the antigen response-induced anti-apoptotic proteins will place these cells at immediate risk for activation-induced cell death resulting in a selective deletion of the subset of antigen-responding lymphocytes. Such intervention will result in immunosuppression that is specific rather than global and will only affect those lymphocytes responding to antigen at the time anti-apoptotic protein production is prevented.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
T lymphocyteantigen presentationantisense nucleic acidapoptosisautoimmunitybiological signal transductioncell population studycellular immunitydisease /disorder modelenzyme linked immunosorbent assayexperimental allergic encephalomyelitisimmunologic memoryimmunopharmacologyimmunoregulationimmunosuppressionimmunotherapylaboratory mousenonhuman therapy evaluationtherapy design /developmenttransport proteins
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
UEI
Project Start Date
01-February-2005
Project End Date
31-January-2006
Budget Start Date
01-February-2005
Budget End Date
31-January-2006
Project Funding Information for 2005
Total Funding
$107,000
Direct Costs
$100,000
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$107,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R43AI063637-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R43AI063637-01
Patents
No Patents information available for 1R43AI063637-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R43AI063637-01
Clinical Studies
No Clinical Studies information available for 1R43AI063637-01
News and More
Related News Releases
No news release information available for 1R43AI063637-01
History
No Historical information available for 1R43AI063637-01
Similar Projects
No Similar Projects information available for 1R43AI063637-01